Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-22

Study Completion Date

2024-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

NCT03197298

Acute Coronary Syndrome Percutaneous Coronary Intervention Drug-Eluting Stents

COMPLETED

Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)

NCT01701453

Acute Coronary Syndrome

UNKNOWN NA

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335

Bleeding Complications

COMPLETED PHASE4

Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial

NCT03431142

Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage

COMPLETED PHASE4

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217

Percutaneous Coronary Intervention Dual Antiplatelet Therapy Aspirin +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with thrombocytopenia are at an increased risk of both bleeding and ischemic events following PCI; however, there is a paucity of data on how to optimally manage these risks. Data indicates that ticagrelor is associated with reduced ischemic outcomes with an accompanying increased risk of bleed in the broader population. This study will assess P2Y12 agent selection in patients with chronic thrombocytopenia to determine if one better balances risks of ischemic and bleeding events following coronary intervention

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Baseline Thrombocytopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years
* PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
* Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
* At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor